Caffeine Inhibits Direct and Indirect Angiogenesis in Zebrafish Embryos.
Animals
Caffeine
/ pharmacology
Cell Line, Tumor
Embryo, Nonmammalian
Embryonic Development
/ drug effects
Fibroblast Growth Factor 2
/ genetics
Gene Expression Regulation, Developmental
/ drug effects
Heterografts
Humans
In Situ Hybridization
Neovascularization, Pathologic
/ drug therapy
Neovascularization, Physiologic
/ drug effects
Zebrafish
/ genetics
FGF2
angiogenesis
caffeine
embryonic vascular development
methylxanthines
zebrafish
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
03 May 2021
03 May 2021
Historique:
received:
14
02
2021
revised:
19
04
2021
accepted:
20
04
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
22
6
2021
Statut:
epublish
Résumé
In this study, we report the effects of caffeine on angiogenesis in zebrafish embryos both during normal development and after exposure to Fibroblast Growth Factor 2 (FGF2). As markers of angiogenesis, we measured the length and width of intersegmental vessels (ISVs), performed whole-mount in situ hybridization with
Identifiants
pubmed: 34063734
pii: ijms22094856
doi: 10.3390/ijms22094856
pmc: PMC8124397
pii:
doi:
Substances chimiques
Fibroblast Growth Factor 2
103107-01-3
Caffeine
3G6A5W338E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Development. 2012 Oct;139(20):3859-69
pubmed: 22951644
Anat Cell Biol. 2013 Mar;46(1):57-67
pubmed: 23560237
Circ Res. 2020 Jul 3;127(2):310-329
pubmed: 32833569
PLoS One. 2009 Jun 03;4(6):e5772
pubmed: 19503615
Alzheimers Res Ther. 2013 Dec 19;5(6):64
pubmed: 24351529
Int J Mol Sci. 2017 Mar 09;18(3):
pubmed: 28282918
Dev Biol. 2001 Feb 15;230(2):278-301
pubmed: 11161578
Nat Protoc. 2007;2(11):2918-23
pubmed: 18007628
Anticancer Agents Med Chem. 2018;18(10):1432-1439
pubmed: 29424319
Chem Biol Interact. 2016 Mar 25;248:1-7
pubmed: 26852703
Angiogenesis. 1999;3(4):353-9
pubmed: 14517415
Drug Chem Toxicol. 2012 Oct;35(4):361-5
pubmed: 22313413
J Cardiovasc Dev Dis. 2016 Jun;3(2):
pubmed: 27335817
J Environ Biol. 2011 Mar;32(2):179-83
pubmed: 21882652
Mol Pharmacol. 2007 Aug;72(2):395-406
pubmed: 17488804
Br J Pharmacol. 2013 Oct;170(4):712-29
pubmed: 23962094
Dev Biol. 2016 Jan 1;409(1):114-128
pubmed: 26477558
Vascul Pharmacol. 2009 Jul;51(1):1-7
pubmed: 19217946
J Clin Invest. 2002 Oct;110(7):933-41
pubmed: 12370271
Dev Dyn. 1995 Jul;203(3):253-310
pubmed: 8589427
Development. 2005 Sep;132(18):4193-204
pubmed: 16107477
Cancer Res. 2007 Apr 1;67(7):2927-31
pubmed: 17409396
Eur J Pharmacol. 2018 May 15;827:80-87
pubmed: 29535000
Nat Rev Drug Discov. 2006 Mar;5(3):247-64
pubmed: 16518376
Acta Pharmacol Sin. 2021 Mar 4;:
pubmed: 33664417
Oncogene. 2015 Apr 16;34(16):2022-31
pubmed: 24909161
J Cell Mol Med. 2009 Aug;13(8B):2061-2068
pubmed: 18657228
Pharmaceuticals (Basel). 2010 Jul 22;3(7):2333-2361
pubmed: 27713356
Front Physiol. 2016 Mar 08;7:56
pubmed: 27014075
J Vis Exp. 2017 Apr 25;(122):
pubmed: 28518096
Annu Int Conf IEEE Eng Med Biol Soc. 2013;2013:3004-7
pubmed: 24110359
Sci Rep. 2016 Nov 28;6:37660
pubmed: 27892483
Drug Des Devel Ther. 2018 Aug 06;12:2423-2430
pubmed: 30122900
FASEB J. 2004 Dec;18(15):1943-5
pubmed: 15448110
J Appl Toxicol. 2016 Feb;36(2):285-95
pubmed: 26179615